We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lanreotide Autogel®: A Review of its Use in the Management of Acromegaly.
- Authors
Croxtall, Jamie D.; Scott, Lesley J.
- Abstract
Lanreotide Autogel (ATG) [Somatuline Depot] is a novel, long-acting preparation of the somatostatin analogue lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of acromegaly and, relative to most other licensed agents, it has a favourable pharmacokinetic profile that permits administration once every 2842 days.Subcutaneous lanreotide ATG was an effective and generally well tolerated treatment in patients with acromegaly in well designed trials and extension studies of up to 4 years duration. It was shown to be no less effective than intramuscular lanreotide long-acting (LA) microparticles treatment in these studies, with more limited data showing that lanreotide ATG therapy was as effective as intramuscular octreotide long-acting repeating (octreotide LAR) treatment. While both of these latter agents offer the advantage of treatment once every 28 days, lanreotide ATG also has the advantage of being available in a convenient pre-filled syringe and is given subcutaneously rather than intramuscularly like other somatostatin analogues. Thus, it provides a valuable first-line option for the management of patients with acromegaly.
- Subjects
ACROMEGALY treatment; SOMATOSTATIN; SOMATOTROPIN; GROWTH factors; ISLANDS of Langerhans; BONE diseases; HYPOGLYCEMIC agents; GASTROINTESTINAL hormones; MEDICAL research
- Publication
Drugs, 2008, Vol 68, Issue 5, p711
- ISSN
0012-6667
- Publication type
Article
- DOI
10.2165/00003495-200868050-00013